| Authors: |
Oh DY; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ohdoyoun@snu.ac.kr., He AR; Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA., Qin S; Cancer Center of Nanjing, Jinling Hospital, Nanjing, China., Chen LT; Kaohsiung Medical University Hospital and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan., Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Kim JW; Medical Oncology, Seoul National University Bundang Hospital, Seoul, Republic of Korea., Suksombooncharoen T; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand., Lee MA; Seoul St. Mary's Hospital, College of Medicine, Cancer Research Institute, The Catholic University of Korea, Seoul, Republic of Korea., Kitano M; Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan., Burris HA; Drug Development Department, Sarah Cannon Research Institute, Nashville, Tennessee, USA., Bouattour M; Medical Oncology, AP-HP Hôpital Beaujon, Paris, France., Tanasanvimon S; Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand., Zaucha R; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Avallone A; Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy., Cundom J; Medical Oncology, Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina., Kuzko A; Oncology R&D, AstraZeneca, Warsaw, Poland., Wang J; Oncology R&D, AstraZeneca, New York, New York, USA., Xynos I; Oncology R&D, AstraZeneca, Cambridge, UK., Vogel A; Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Medical School Hannover, Hannover, Germany., Valle JW; Research, Cholangiocarcinoma Foundation, Herriman, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK. |
